



A 2025 VISION FOR CATALONIA


Scaling-up the BioRegion of Catalonia

The background image shows a close-up of a modern building's exterior. On the left, there's a vertical strip of reddish-brown panels with a wood-grain texture. To its right is a large, light blue glass pane with a white metal frame. The sky above is a clear, vibrant blue.

**Biocat is the
organization
that champions
the healthcare
and life sciences
ecosystem in
Catalonia**

What is biocat?

A Government of Catalonia initiative born in 2006 with the mission of maximizing the economic and societal impact of the life sciences and healthcare innovation in the BioRegion



Catalonia is
the leading
BioRegion in
Spain and one
of the top five
in Europe



Who is behind?



Public Administration

Government of Catalonia
#Presidency
#Health Department
#Economy and Knowledge Department
#Enterprise & Labor Department
#Agriculture Department

Barcelona City Council
#Economy & Promotion Area



Public Institutions

ACUP -Catalan Association of Universities-

ACER -Catalan Association of Research Centers-

HOSP -Catalan Hospital Network-

XPCAT -Catalan Science Park Network-



Private Sector

#5 FARMAINDUSTRIA -Spanish Association of Pharma Companies-

#3 CATALONIABIO & HEALTHTECH -Catalan Association of Biomedicine and Health Companies-

#2 FENIN -Spanish Platform for Innovation in Technology Healthcare-

#1 COMB -Official Medical College of Barcelona-

2 PRIVATE COMPANIES



One of the main strategic priorities is accelerate business in life sciences and healthcare in Catalonia

Strategic priorities



GROW INNOVATION & ACCELERATE BUSINESS

Providing life sciences and healthtech companies/projects with tailored programs at every stage of their growth, with special emphasis on the knowledge and technology transfer, commercialization, building teams and access to capital, from start-up to scale-up



DEVELOPE TALENT & BOOST KNOWLEDGE

Providing innovative training and programs that empower researchers and entrepreneurs with the mindset, skills and the network to bring healthcare solutions to the market



POSITION BIOREGION INTERNATIONALLY

Promote and showcase the BioRegion of Catalonia brand to be globally renowned for its excellence in science and healthcare innovation, increasing the opportunities to attract investment and talent. Place the BioRegion among the top 3 leading European innovation's hubs

Talent,
innovation &
acceleration
programs to
attract foreign
investment &
position the
BioRegion
globally



Programs overview

TALENT & KNOWLEDGE

Key metric: people trained

d·HEALTH
Barcelona

Short
Programs

B·Debate

Keys to
Entrepreneurship
in Bio & Medtech

INNOVATION & ACCELERATION

Key metric: projects/companies accelerated

CRAASH
Barcelona

Investment
Readiness

Open Innovation
Forum

Health & Bio
Team dating

Here Comes
Your Lead

MARKETPLACES

INTERNATIONAL POSITIONING

Key metric: impacts in reports/media

BioRegion
Report

Catalan Life
Sciences
Platform

Fairs &
Missions

Strategic
Partnerships

SUPPORT ACTIVITIES & RESOURCES

Communications &
Promotions

Business
Intelligence

Innovation
Advising

European
Funds/Tools

Job Board

Networks &
Connections

KEY LIAISONS

Government (Health,
Industry, Knowledge)

Accelerators &
Incubators

Associations (CataloniaBio & HealthTech, Barcelona Tech City,
FENIN, Farmaindustria, Asebio, ITEMAS)

International
Networks
(EIT Health, CEBR)

Talent & Innovation acceleration programs

Health & Bio Team Dating

H&B brings together scientists & research groups working in the life sciences with business people to generate new business synergies and start-ups




The Investment Readiness Series

Increasing deal flow of projects ready for investment in the BioRegion.
Matching the right investors with the right projects



Here Comes Your Lead

A program to bring early-stages of drug discovery in therapeutics into target validation and hit-to-lead or lead optimization



Open Innovation Forum

Companies share innovation challenges and get proposals from research groups and centers. Focused on food, healthcare, medical technology, chemistry and materials



International positioning


BioRegion Report

Global Outlook Report
on the state of the
healthcare and life
sciences industry in
Catalonia



Strategic Partnerships

Biocat establishes
strategic partnerships to
position the Catalan life
sciences and healthcare
ecosystem on an
international level



Catalan Life Sciences Platform

An accurate database that
aims to feature companies
and organizations that
work in the life sciences
and healthcare industry in
Catalonia

Fairs & missions

1,400+ entities &
companies participated
in international events
attracted or promoted by
Biocat in the past 10
years





Destination
of choice for
multinational
companies

Barcelona: a growing innovation hub in Europe

amazon

facebook

Microsoft

SIEMENS

Allianz

ORACLE



moodle

king


hp

SATELLLOGIC



Key
ecosystem
players at
walking
distance









Top-notch
scientific
excellence
in the
BioRegion




Barcelona is #34 in science output worldwide (and #8 in Europe)



The top 500 cities by scientific output in 2017



Catalonia is currently one of the leading scientific hubs in Europe




Investment
that creates
value



Finance raised is on upward trend, especially private investment

Investment in startups, in €M




International investors are increasing

50

International investors

(x10 in just 5 years)



Success stories in fundraising

€11-50 M
Invested



€1-10 M
Invested



'15

'16

'17

'18

'19


Life Sciences venture financing (€M) by country (2000-2017)



A close-up photograph of a modern building's exterior. The building features a glass facade with a grid of dark frames and a steel frame structure. The background is a clear blue sky.

**At least,
10 advanced
products are
expected to
reach patients
by 2025**

20 New therapies advancing the pipeline



And what's
on the
BioRegion?



Last months in the BioRegion

NS MEDICAL DEVICES

REGULATION COMPANIES DISRUPTORS EVENTS WEBINARS

Company News

Spanish medical tech company Anaconda Biomed closes €20m funding round

By NS Medical Staff Writer | 05 Dec 2019

DEVICES CARDIOVASCULAR

Anaconda Biomed advanced thrombectomy system features a delivery catheter, funnel-shaped aspiration catheter and a stent retriever



FierceBiotech BIOTECH RESEARCH CRO MEDTECH

Gilead, Aelix ally to trial HIV-suppressing combination

By Nick Paul Taylor | Oct 18, 2018 8:00am

Gilead has teamed up with Aelix Therapeutics to trial a combination designed to free people with HIV from the need to take antiretroviral drugs. The planned clinical trial will test Gilead's TLR7 agonist in combination with Aelix's T-cell vaccine.

Gilead began testing the TLR7 agonist, vesatolimod, in HIV patients in 2016. In animal models, the combination of the drug and a broadly neutralizing antibody suppressed HIV for six months without additional treatment. The early-stage finding dashed hopes that vesatolimod can boost immune responses and thereby contribute to the elimination of virus-infected cells.

Vesatolimod may need support to achieve HIV suppression, though. That's where Aelix comes in. The Spanish biotech is developing a T-cell vaccine designed to orchestrate immune attacks on vulnerable parts of HIV. Aelix's interest in the approach grew out of research into people who are normally more able to control HIV infections. Analysis of these people showed their T cells go after certain regions of HIV, suggesting this may be the key to controlling the virus.

THE PE HUB NETWORK
A COMMUNITY FOR PROFESSIONALS IN PRIVATE CAPITAL

PE HUB NETWORK BUYSOUTS VC ACTIVE LPs PRATTS PARTNERCONNEC

Home News Briefs Opinion Jobs Videos Members Podcasts Emergencies

Mediktor fetches \$3.4 mln Series A

December 11, 2018 By | CISION News Products Contact

Print Email

Brooklyn, New York—Mediktor, a medical device company focused on improving decision-making in the operating room, has closed a \$3.4 million Series A financing round. The round was led by ABAC Therapeutics, with participation from Foresight Medical Ventures, and other investors.

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

Proceeds to support development of multiple novel first-in-class antibiotics

FierceBiotech BIOTECH RESEARCH CRO MEDTECH

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/II) at the 'Clinical Trials on Alzheimer's Disease' (CTAD) congress on October 27, 2018 in Barcelona.

- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma therapy has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients.

FierceBiotech BIOTECH RESEARCH CRO MEDTECH

Qiagen inks \$191M deal to buy infection test panel firm STAT-Dx

By Nick Paul Taylor | Feb 2, 2018 4:40am

Qiagen has agreed to a \$191 million deal to acquire STAT-Dx. The takeover will give Qiagen control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.

STAT-Dx's tests use its DiaCart® cartridges and accompanying analyzer. The single-use cartridges feature ports for swabs and tissue or liquid samples. After loading the cartridge, the user slots it into the analyzer. This consists of an operational module with a screen and one or more analytical modules. Each analytical module has a slot in the top for the DiaCart® cartridges.

ns Categories Events Podcasts Jobs Reports Newsletter Company REGISTER

Barcelona-based mental health startup Psious raises €8 million

By Andreu Díezler | May 7th, 2019

FierceBiotech BIOTECH RESEARCH CRO MEDTECH

Roche-backed Minoryx raises €21M to expand CNS R&D

by Nick Paul Taylor | Sep 26, 2018 8:50am

Minoryx has raised €9.1 million in series B funding. This round rates Minoryx as an emerging clinical-stage company.

CISION News Products Contact

News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture

SOM Biotech Closes a Financing Round of 7M Euros

Bloomberg

DGAP-News: Oryzon Genomics SA: Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors

29 de octubre de 2018 9:00 CET

DGAP-News: Oryzon Genomics SA / Key words: Capital Increase, Oryzon Genomics SA, Oryzon Raises EUR 13 million through a Private Placement with US and European Investors

29 de octubre de 2018 9:00 CET

The issuer is solely responsible for the content of this announcement.

Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors

29 de octubre de 2018 9:00 CET


The issuer is solely responsible for the content of this announcement.

Market News: Oryzon Genomics SA / Key words: Capital Increase, Oryzon Genomics SA, Oryzon Raises EUR 13 million through a Private Placement with US and European Investors

29 de octubre de 2018 9:00 CET

The issuer is solely responsible for the content of this announcement.


BRODCAST, SPAIN AND CARRIBEAN, MA, UNITED STATES, OCTOBER 29, 2018 - Oryzon Genomics SA (Oryzon) has announced the completion of a public clinical-stage capital increase. Through this offering, leveraging syndication to develop therapies to address a strong unmet medical need, today announced the successful conclusion of a capital increase of 4,081,022 new common shares, for gross proceeds exceeding EUR 13 million issued at a



Many hubs
start-up...
just a few
scale-up

1

2025 Vision for Catalonia





www.bioregioncatalonia.cat



www.bioregioncatalonia.cat

